In this weeks episode we learn that not only does James Bond have amazing espionage skills but also an impenetrable immune system. 
  
Tom celebrates the Phase II//III results for antiviral drug "Paxlovid" against SARS-COV-2 and dives into the events at COP26 while Evan evaluates the controversial approval of a new Alzheimer's drug, Aducanumab, and examines what the clinical trial results actually said.

In this weeks episode we learn that not only does James Bond have amazing espionage skills but also an impenetrable immune system. Tom celebrates the Phase II//III results for antiviral drug "Paxlovid" against SARS-COV-2 and dives into the events at COP26 while Evan evaluates the controversial approval of a new Alzheimer's drug, Aducanumab, and examines what the clinical trial results actually said.

In this weeks episode we learn that not only does James Bond have amazing espionage skills but also an impenetrable immune system.&nbsp;
&nbsp; 
Tom celebrates the Phase II//III results for antiviral drug "Paxlovid" against SARS-COV-2 and dives into the events at COP26 while Evan evaluates the controversial approval of a new Alzheimer's drug, Aducanumab, and examines what the clinical trial results actually said.

28. A Flawed Cure for Alzheimer‘s?

Welcome to The Sceptically Inclined Science Podcast where we talk about science, particularly human sciences, by looking at papers that are both unusual and serious. We hope to have a friendly, light hearted discussion in which we interweave stories from our lives. We don‘t need you to have a huge background in science so please give us a listen and enjoy!

Share 28. A Flawed Cure for Alzheimer‘s?

Sign up to save your podcasts

28. A Flawed Cure for Alzheimer‘s?

28. A Flawed Cure for Alzheimer‘s?